For COPD, serum fucosylation levels of SP-D may serve as a diagnostic biomarker (36), while serum levels of ST6GAL1 may predict acute exacerbation of the disease (57). This evidence concerns the gene ST6GAL1 and chronic obstructive pulmonary disease.